SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
SINOVAC BIOTECH LTD
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026
$6.47+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- 850.08%
SINOVAC BIOTECH LTD revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Construction Supervisor Service | $24.00K | – | – | – | – | – | – | – | – | – | 0.0% | – |
| Mumps Vaccines | – | – | – | – | – | – | $19.73M | $1.66M | $1.67M | $477.00K | – | – |
| Influenza vaccines | – | – | – | – | – | – | – | – | $13.54M | $9.83M | – | – |
| H5N1 | – | – | – | – | – | – | – | – | $0 | $6.39M | – | – |
| Inactivated hepatitis vaccines | – | – | – | – | – | – | – | – | $37.85M | $20.60M | – | – |
| Enterovirus 71 vaccines | – | – | – | – | – | – | $149.22M | $162.54M | $121.28M | $35.14M | – | – |
| Inactivated hepatitis vaccines | – | – | – | – | – | – | $57.95M | $63.43M | $37.85M | $20.60M | – | – |
| Influenza vaccines | – | – | – | – | – | – | $19.15M | $2.03M | $13.54M | $9.83M | – | – |
| Grants For H5N1 2013 Vaccines | – | – | – | – | – | – | – | – | – | $6.39M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China | $261.18M | $297.00M | $402.96M | $1.07B | $10.90B | $365.62M | $227.11M | $215.12M | $172.90M | $71.18M | 67.7% | -12.1% |
| Outside Chinese Mainland | $124.83M | $64.37M | $67.21M | – | – | – | – | – | – | – | 32.3% | +93.9% |
| Foreign countries | – | – | – | – | – | – | $18.94M | $14.53M | $1.45M | $1.25M | – | – |
| Outside Mainland China | – | $64.37M | $67.21M | $398.74M | $8.47B | $145.00M | $18.94M | $14.53M | – | – | – | – |
From the segment and revenue-disaggregation notes of Sinovac Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.